TD Asset Management
MRNA icon

TD Asset Management’s Moderna MRNA Stock Holding History

TD Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3M Buy
318,122
+138,539
+77% +$7.17M 0.02% 487
2026
Q1 		$9.12M Buy
179,583
+119,360
+198% +$5.57M 0.01% 669
2025
Q4 		$1.78M Sell
60,223
-890
-1% -$24.2K ﹤0.01% 1009
2025
Q3 		$1.58M Sell
61,113
-700
-1% -$19.5K ﹤0.01% 1015
2025
Q2 		$1.71M Sell
61,813
-64,456
-51% -$1.7M ﹤0.01% 976
2025
Q1 		$3.58M Sell
126,269
-8,985
-7% -$319K ﹤0.01% 834
2024
Q4 		$5.62M Sell
135,254
-12,930
-9% -$618K 0.01% 775
2024
Q3 		$9.74M Sell
148,184
-13,953
-9% -$1.28M 0.01% 648
2024
Q2 		$19.3M Buy
162,137
+19,599
+14% +$2.48M 0.02% 504
2024
Q1 		$15.2M Buy
142,538
+1,639
+1% +$165K 0.01% 546
2023
Q4 		$14M Sell
140,899
-18,692
-12% -$1.57M 0.01% 559
2023
Q3 		$16.5M Sell
159,591
-3,833
-2% -$428K 0.02% 472
2023
Q2 		$19.9M Sell
163,424
-20,171
-11% -$2.69M 0.02% 441
2023
Q1 		$28.2M Sell
183,595
-43,723
-19% -$7.21M 0.03% 365
2022
Q4 		$40.8M Sell
227,318
-52,754
-19% -$8.63M 0.05% 294
2022
Q3 		$33.1M Buy
280,072
+1,479
+0.5% +$224K 0.04% 314
2022
Q2 		$39.8M Buy
278,593
+27,507
+11% +$3.93M 0.05% 299
2022
Q1 		$43.3M Buy
251,086
+441
+0.2% +$74.2K 0.04% 318
2021
Q4 		$63.7M Sell
250,645
-3,620
-1% -$1.06M 0.05% 271
2021
Q3 		$97.9M Buy
254,265
+5,529
+2% +$2.04M 0.1% 162
2021
Q2 		$88M Buy
248,736
+77,922
+46% +$13.9M 0.09% 187
2021
Q1 		$22.4M Buy
170,814
+35,402
+26% +$5.13M 0.03% 439
2020
Q4 		$14.1M Buy
135,412
+27,523
+26% +$2.78M 0.02% 509
2020
Q3 		$7.63M Buy
107,889
+48,688
+82% +$3.39M 0.01% 605
2020
Q2 		$3.8M Buy
59,201
+34,882
+143% +$1.91M 0.01% 719
2020
Q1 		$728K Buy
+24,319
New +$559K ﹤0.01% 1081
2019
Q4 		– Sell
-20,806
Closed -$331K – 1412
2019
Q3 		$331K Buy
20,806
+1,400
+7% +$20.7K ﹤0.01% 1237
2019
Q2 		$284K Buy
+19,406
New +$417K ﹤0.01% 1253

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

TD Asset Management's MRNA Position: Q2 2026 in Review

TD Asset Management increased its Moderna (MRNA) stake by 77% in Q2 2026, buying an estimated $7.17M and bringing the position to 318,122 shares worth $22.3M. The position accounts for 0.02% of the portfolio, ranked #487.

TD Asset Management first reported a position in MRNA in Q2 2019 and has held it in 28 quarters since. The position peaked at $97.9M in Q3 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • TD Asset Management held 318,122 shares of Moderna worth $22.3M as of Q2 2026.
  • TD Asset Management bought 138,539 Moderna shares in Q2 2026, an estimated $7.17M.
  • Moderna made up 0.02% of TD Asset Management's portfolio in Q2 2026, its #487 holding.
  • TD Asset Management first reported a position in Moderna in Q2 2019 and has held it in 28 quarters since.
  • TD Asset Management's Moderna position peaked at $97.9M in Q3 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.